Stage II metaplastic breast cancer in a 47-year-old man

Patient Info: Anonymized, Male, 40s | Stage II

Biomarkers: ER 1%; PR negative; HER2 negative; E-cadherin positive; p63 positive; genetic testing reported no abnormal mutations

Two years after surgery he was doing well, with only occasional pain at the mastectomy site and a negative recent mammogram of the left breast.

PubMed CentralRead more →

Triple receptor-positive neuroendocrine breast cancer in a 32-year-old woman

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: ER positive; PR positive; HER2 positive; neuron-specific enolase positive; synaptophysin positive

She was stable on follow-up and was receiving adjuvant chest-wall radiation plus systemic chemotherapy and trastuzumab-based therapy.

PubMed CentralRead more →

Metastatic Lobular Breast Cancer With Long-Term Disease Control Across Multiple Therapies

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: Initial tumor: ER negative, HER2 negative, Ki67 17%. 2006 recurrence: ER 40%

Metastatic Site: pleura, liver, skin, bone

She was alive on ongoing metronomic vinorelbine with substantial disease stabilization at the most recent follow-up.

PubMed CentralRead more →

Breast cancer returning 21 years later as a solitary parotid metastasis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Parotid metastasis ER positive; PR positive; HER2 borderline by IHC but FISH 1.82

Metastatic Site: left parotid gland

More than 5 months after the parotid metastasis was diagnosed, the tumour had slightly decreased in size and her metastatic disease remained stable on endocrine therapy.

PubMed CentralRead more →

Breast cancer returning years later in the biceps muscle

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER positive

Metastatic Site: left biceps muscle

Her arm symptoms improved considerably after radiotherapy, and MRI 6 months later showed a significant decrease in the size of the biceps tumour.

PubMed CentralRead more →

Male Breast Cancer Treatment Complicated by Stevens-Johnson Syndrome

Patient Info: Anonymized, male, 60s

After the third chemotherapy cycle he developed severe Stevens-Johnson syndrome with disseminated intravascular coagulation and multiorgan failure, and he died after care was shifted to comfort measures.

PubMed CentralRead more →

Stage III HER2-Positive Invasive Ductal Carcinoma: Dorothy's Survivor Story

Patient Info: Dorothy Paterson, Female, 40s | Stage III

Biomarkers: HER2-positive

As of November 2016, Dorothy had remained cancer-free since completing treatment for Stage III HER2-positive invasive ductal carcinoma in April 1999.

MD AndersonRead more →

Stage III Inflammatory Breast Cancer Diagnosed After Severe Breast Pain and Swelling Following Mammography

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ER negative, PR negative, HER2 highly positive

After later metastatic disease was found, she chose no further active treatment and died of progressive disease in 2012.

PubMed CentralRead more →

Mixed epithelial and mesenchymal metaplastic breast carcinoma: no recurrence 1 year after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Mixed metaplastic breast cancer: epithelial part ER/PR/HER2-positive; mesenchymal part ER/PR-negative with weak HER2. Ki-67 ~20%.

As of March 2014, she was doing well with no recurrence or metastasis 1 year after modified radical mastectomy, adjuvant CEF/Taxotere chemotherapy, and tamoxifen.

PubMed CentralRead more →

Breast invasive ductal carcinoma with coexisting inflammatory myofibroblastic tumor: disease-free after mastectomy, TAC, and tamoxifen

Patient Info: Anonymized, Female, Under 40

Biomarkers: Breast cancer: ER/PR-positive with HER2 2+ and p53-positive. Separate inflammatory myofibroblastic tumor had ALK/vimentin/actin/S-100 markers.

As of August 2013, she remained disease-free 2 years after modified radical mastectomy, 6 courses of TAC chemotherapy, and tamoxifen.

PubMed CentralRead more →

BRCA1-associated right invasive ductal carcinoma followed by left acinic cell carcinoma of the breast

Patient Info: Anonymized, Female, 40s

Biomarkers: Constitutional BRCA1 mutation. Right breast cancer was ER/PR positive, HER2 negative; later left tumor was triple-negative with TP53 change.

After treatment for right invasive ductal carcinoma and later contralateral acinic cell carcinoma, she was alive and well 19 months after the acinic cell carcinoma surgery, with no evidence of disease while continuing hormonal therapy.

PubMed CentralRead more →

Hormone-positive breast cancer with axillary recurrence responding to hyperthermia, radiation, and chemotherapy

Patient Info: Anonymized, Female, 60s

Biomarkers: ER-positive; PR-positive; HER2-negative

The left axillary recurrence enlarged during weekly paclitaxel and radiotherapy, then became nearly flat and was assessed as a complete response 8 weeks after adding hyperthermia.

PubMed CentralRead more →

Recurrent HER2-amplified breast cancer: complete remission on trastuzumab-based therapy

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Biomarkers: Primary tumor was ER/PR negative and HER2 not amplified. Recurrent lymph-node disease became ER/PR positive and HER2 amplified by FISH.

Metastatic Site: left axillary and infraclavicular lymph nodes

After HER2-amplified nodal recurrence, paclitaxel plus trastuzumab produced complete clinical remission; she continued trastuzumab monotherapy with tolerable neuropathy.

PubMed CentralRead more →

ER-positive breast cancer recurrence after DCIS: chemotherapy, nodal surgery, radiation, and endocrine therapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Recurrent invasive breast cancer: ER-positive; HER2/neu-negative. PR not reported.

Disease-free for 33 months after treatment of ER-positive, HER2-negative invasive breast cancer recurring in the mastectomy skin flap with positive axillary sentinel nodes.

PubMed CentralRead more →